328 related articles for article (PubMed ID: 17687358)
1. A better prescription for drug-development financing.
Kessel M; Frank F
Nat Biotechnol; 2007 Aug; 25(8):859-66. PubMed ID: 17687358
[No Abstract] [Full Text] [Related]
2. Biotechnology partnerships--medicine for an ailing industry?
DeLamarter J
Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
[No Abstract] [Full Text] [Related]
3. Does biotech M&A benefit investors?
Jacobs T
Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
[No Abstract] [Full Text] [Related]
4. The 802 million dollars fallacy.
Hodgson J
Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
[No Abstract] [Full Text] [Related]
5. A reprise for collaborative financing in biotech.
Ransom J
Nat Biotechnol; 2006 Aug; 24(8):873-4. PubMed ID: 16900110
[No Abstract] [Full Text] [Related]
6. Shareholders flex their muscles.
Thiel K
Nat Biotechnol; 2008 Jan; 26(1):19-21. PubMed ID: 18183007
[No Abstract] [Full Text] [Related]
7. GSK moves on Sirtris.
Sipp D
Nat Biotechnol; 2008 Jun; 26(6):595. PubMed ID: 18536662
[No Abstract] [Full Text] [Related]
8. By the numbers. Largest healthcare financing companies ranked by amount of syndicated loans in the healthcare sector underwritten from Sept. 1, 2006, through April 9, 2007.
Mod Healthc; 2007 May; 37(21):46. PubMed ID: 17824191
[No Abstract] [Full Text] [Related]
9. Cash-strapped biotechs find financing alternative.
Mitchell P
Nat Biotechnol; 2004 Sep; 22(9):1057-8. PubMed ID: 15340452
[No Abstract] [Full Text] [Related]
10. Millennium ends Takeda's US shopping spree.
Sipp D
Nat Biotechnol; 2008 Jun; 26(6):593-5. PubMed ID: 18536661
[No Abstract] [Full Text] [Related]
11. Other investors also on healthcare trail.
Galloro V
Mod Healthc; 2002 Mar; 32(9):31. PubMed ID: 11922008
[No Abstract] [Full Text] [Related]
12. Your capital strategy plan and deliver.
Walters SM; Nokels KJ
Healthc Financ Manage; 2004 May; 58(5):78-83. PubMed ID: 15162759
[TBL] [Abstract][Full Text] [Related]
13. The quiet revolution.
Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
[No Abstract] [Full Text] [Related]
14. Can Europe accelerate out of trouble?
Nat Biotechnol; 2006 Sep; 24(9):1040. PubMed ID: 16964194
[No Abstract] [Full Text] [Related]
15. Maturing biotechs turn to pharma's markets.
Ratner M
Nat Biotechnol; 2005 Mar; 23(3):269. PubMed ID: 15765067
[No Abstract] [Full Text] [Related]
16. Make no small plans. Easy-to-track finances of private healthcare services draw attention--and big money--from equity investor firms.
Galloro V
Mod Healthc; 2002 Mar; 32(9):30-2. PubMed ID: 11922007
[No Abstract] [Full Text] [Related]
17. Mixing drugs. Latest pharma deals unlikely to affect prices: experts.
Galloro V
Mod Healthc; 2009 Mar; 39(11):14. PubMed ID: 19415830
[No Abstract] [Full Text] [Related]
18. R&D technology investments: misguided and expensive or a better way to discover medicines?
Schmid EF; Smith DA
Drug Discov Today; 2006 Sep; 11(17-18):775-84. PubMed ID: 16935744
[TBL] [Abstract][Full Text] [Related]
19. Equity financing of capital acquisitions.
Jones KR
Semin Nurse Manag; 2000 Mar; 8(1):5-6. PubMed ID: 11075180
[No Abstract] [Full Text] [Related]
20. Biotechs recoil at hedge fund manager's patent attacks.
Senior M
Nat Biotechnol; 2015 Jul; 33(7):680-1. PubMed ID: 26153996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
